Alquist's (1948) classification of adrenergic receptors began our understanding of the physiological processes at adrenergic nerve endings. The synthesis, storage, release and inactivation of catecholamines have been extensively investigated, particularly in the cardiovascular and central nervous systems. A galaxy of pharmacological agents have become available as receptor agonists and antagonists to mimic block or modulate trans mitter function. In recent years, the possi bility of altered responsiveness with age has added another dimension to physiological and pharmacological studies of the autonomic nervous system. Clinical assessment of the autonomic ner vous system has depended largely on the measurement of cardiovascular reflexes. With the development of pupillometry, the iris has emerged as a useful additional model for measurement of autonomic responses. Drugs affecting the autonomic nervous system are widely used in the management of a variety of ocular disorders. However, the physiological mechanisms underlying autonomic function in the eye remain poorly defined and more specific use of pharmacological agents would result from improved understanding. Atten tion has focused on beta-adrenoceptors since the introduction of ophthalmic beta blockers in 1976. The object of this paper is to discuss the relatively limited amount of data available on the role of alpha-adrenoceptors in the eye.
Alpha adrenoceptors: sites and functions
Alpha-adrenoceptors can be divided into alpha! and alpha2 subtypes based on the rela tive potencies of agonist and antagonist drugs and independent of receptor location. Both subtypes are present centrally and periph erally. Post junctional alpha ! and alpha2 adre noceptors mediate contraction of smooth muscle. Prejunctional alpha2 adrenoceptors are known to inhibit the release of nor adrenaline by sympathetic postganglionic fibres. Modulation of neurotransmission by alpharadrenoceptors is better defined in per ipheral tissues than in the central nervous system. ! Alpha-adrenoceptors are widely dis tributed in the eye, 2 especially in the smooth muscle cells of the iris, the blood vessels of the conjunctiva as well as those of the ciliary pro cesses and the aqueous outflow tract. The dis tribution and density of alpha-subtypes in ocular structures, an important determinant of drug response, varies considerably between species. Localisation of receptor sites by bind ing studies have been largely carried out in animal preparations. Iris-ciliary body prep- arations from rabbits have been shown to con tain predominantly beta2 adrenoceptors with a large population of alphaz-adrenocepWrs also present. 3 Beta2 adrenoceptors have also been predominantly isolated in cultured human trabecular cells and bovine non-pig mented ciliary epithelial cells. 4
Alpha-adrenoceptors and the iris
In the iris, alpha,-adrenoceptors mediate the contraction of the dilator pupillae. Phe nylephrine is a selective alpha agonist which results in maximum mydriasis in 60 minutes,5 varying in extent with the degree of pigmenta tion of the iris. 6 A concentration of 5 per cent phenylephrine is sufficient to achieve a maxi mum response despite the widespread clinical usage of 10 per cent.7 It has been suggested that increased sensitivity of alpha,-adre noceptors accompanies a reduction in sympa thetic tone in the elderly.H In a recent study5, comparing the mydriatic response to phe nylephrine in elderly and young age groups, the maximum dilatation reached was similar in both age groups. When the difference in baseline pupil size was eliminated by the administration of thymoxamine, a selective alpha, antagonist, the mydriatic response was was the same in both groups. While there appears to be a reduced sympathetic dilator tone in the elderly, there is not the increased sensitivity of alpha,-adrenoceptors expected with denervation hypersensitivity. The reduc tion in pupil size associated with age must be caused by either a central effect or a deficiency in a key intracellular coupling step beyond the alpha, receptor. Investigations in the rabbit iris-ciliary body suggest that alterations in the phosphoinositide hydrolysis system and its derived second messenger may explain altered responses to alpha,-adrenoceptor stimulation. 9 Measurement of pupil size following the administration of alpha2 agonists has yielded conflicting results.
The traditionally used alpha2 agonist clonidine is relatively non-selective and acts both centrally and peripherally. Given intra venously, clonidine has been reported to pro duce a dose dependent mydriasis in cats and rats, reversed by the alpha2 antagonist yohim bine.1O In human subjects, clonidine (0. 25 per cent) applied topically also produced mydriasis, probably by a direct action on alpha2-adrenoceptors in the iris. II Clonidine given intravenously to healthy volunteers in low doses of 0. 1 mg and 0. 2 mg, was found to cause miosis reversed by the alpha2 antagonist RX 781094. ' 2 It is likely that at this dose, clonidine is acting centrally to reduce sympa thetic tone to the iris, thus producing para sympathetic dominance and pupillary constriction. Antagonism of the miotic action of clonidine by RX 781094 may also be at centrally located alpha-adrenoceptors. Newer selective alpha2 agonists such as B-HT920 topically applied in rabbits, pro duced no change in pupil sizeY The absence of mydriasis with these newer agents has cre ated an interest in the role of alpha stimulating drugs as ocular hypotensive agents.
Alpha adrenoceptors and retinal blood vessels
The blood vessels of the retina and optic disc autoregulate in order to maintain an almost constant blood flow despite changes in arterial or intraocular pressure. '4 The tissue levels of oxygen and carbon dioxide2 are mainly responsible for this auto regulation. However, retinal vessels have been shown to have specific binding sites for the binding of catecholamines and angiotensin. '4 These specific adrenergic binding sites must be located to understand if they sites are func tional receptors that help maintain haemodynamic homeostasis, and to deter mine if their stimulation modifies the auto regulatory capabilities of these vessels under physiological or pathological circumstances. Limitation of autoregulation may be the reason that some individuals suffer glaucomatous optic nerve damage while others with intact regulation may not suffer damage.
Alpha-adrenoceptors and aqueous humour dynamics
Intraocular pressure is determined by the balance between inflow and outflow of aque ous humour 2 . Effects of phenylephrine (alpha, agonist), prazosin (alpha, antagonist), clonidine (alpha2 agonist), and yohimbine (alphaz antagonist), on aqueous humour dynamics have been studied with a cat eye model. 1 5 Phenylephrine inhibited outflow more than formation, causing an ocular hypertensive effect. Prazosin suppressed for mation more than outflow. However, its effect on outflow is sufficient to limit its usage as a clinically effective ocular hypotensive agent. Both clonidine and yohimbine influenced aqueous humour formation more than out flow and thus lowered intraocular pressure. The conventional theory of receptor antago nism did not function at alpharreceptor sites in the cat model. In the rabbit, stimulation of the alpha2 subtype with the selective agonist B-HT920 re ' sulted in a decreased intraocular pressure which was blocked by yohimbine. 1 3 Topical prazosin has also been shown to lower intraocular pressure in rabbits, an effect inde pendent of the effect on systemic blood pressure. 16 While the systemic effects of clonidine and prazosin limit their use in the eye, phar macological studies are aimed at identifying dominant receptors at both inflow and out flow tracts. The development of selective alpha2 agonists may yield a new class of anti glaucomatous drugs, free of mydriatic response and systemic side effects. The alphal agonist phenylephrine has been shown to pro duce a biphasic effect on intraocular pressure an initial rise followed by a late occurring fallY Phenylephrine is not used clinically in man as an ocular hypotensive agent because of the risk of acute angle closure glaucoma. The alphal antagonist thymoxamine, how ever, is used in the management of acute glaucoma, lowering intraocular pressure by overcoming pupil block. 18
Conclusion
Animal models have been used in phar macological investigations that are not permissible in the human eye. The dis advantage of most animal models, with the exception of sub-human primates, is the varia tion in population and distribution of receptor subtypes, and the differences in anatomy of the irido corneal angle.
Clinical assessment of autonomic function includes pupillometry, which can provide some answers in relation to the neural control of the iris and aqueous flurophotometry which has been used in the study of aqueous humour dynamics. However, the physiological mecha nisms underlying autonomic function in the eye remain poorly defined.
Current interest in adrenergic agents has focused on the management of chronic simple glaucoma. Many adrenergic agents provide a significant clinical reduction of intraocular pressure. Both alpha2 agonist and antagonist drugs have been shown to lower intraocular pressure. The same paradox exists with beta receptors as both beta agonists and antago nists lower intraocular pressure. Early studies of the ocular response to adrenergic agents were done with drugs having relatively poor receptor specificity. I'! Adrenaline, for example, stimulates both alpha and beta adre nergic receptors and shows little selectivity for pre-or post-synaptic sites. In addition to non selectivity, ocular absorption, intraocular drug distribution and metabolism must influ ence the response to adrenergic agents.
Precise identification, localisation and characterisation of the receptors involved in aqueous humour dynamics are prerequisites to further studies of biochemical cellular events. The receptor is only the initial inter face of drug action and transient events at this level initiate further intracellular responses.
Anatomical localisation of receptors in man has recently advanced using membranes pre pared by isopycnic centrifugation of tissue homogenates and by slide mounted sections of human trabecular meshwork with in vitro labelling light microscopic autoradiography. These studies have demonstrated predomi nantly beta2 adrenergic receptors in human iris ciliary body preparations ?) and trabecular endothelial cells. 2 1
At the present time, the quantitative distri bution and subtype of alpha receptors in the intraocular muscle fibres, the blood vessels or other cell types in the iris ciliary body has not been established in man or in animals. 22 It is likely that alpha antagonists can involve different receptor mechanisms to affect the regulation of aqueous humour dynamics. The reduction in intraocular pressure following their administration may result from a decreased rate of aqueous humour formation, an increase in outflow facility or an increase in uveoscleral outflow. This multiplicity of sites of action for alpha adrenergic drugs makes detailed analysis of their actions in the iris ciliary body particularly difficult.
There is speculation that the proportion of the two alpha subtypes could vary in different ocular vascular beds and between species. Ciliary process haemodynamics are thought to be modulated primarily by alpha, adre nergic receptors in humans, while in the rabbit iris ciliary body, the large number of alpha2 adrenergic receptors probably mediate vascu lar tone. 2 3 Vascular post-synaptic alpha2 receptors cause vasoconstriction by a calcium depen dent mechanism when activated by endo genous agonists. Blockade of such receptors could cause a local vasodilatation of blood vessels in the eye, thus increasing outflow. However, vasodilatation of vessels in the cili ary processes could lower ultrafiltration rate which could account for a decrease in aqueous formation.
Additionally, alpha2 receptors are nega tively coupled to adenylate cyclase in some tissues and can affect both fluid absorption and secretion. It is possible that the secretory capacity of the ciliary epithelium could be directly modulated by the presence of alpha2 receptors on these cells. This represents a second possible ciliary site of action for alpha2 selective drugs which is quite separate from the vascular sites in the ciliary processes.
The mechanism for an increase in uveoscleral outflow by drugs with selectivity for both alpha, and alpha2 receptors might involve simultaneous antagonism of receptors on intraocular muscle cells and on blood vessels.
Studies of alterations of receptor con centration with light microscopic auto radiography in glaucoma and ageing could provide further important information in designing new drugs for the treatment of glaucoma. Topically applied alpha2 antago nists may in the future provide high selectivity with fewer systemic side effects in the reduc tion of intraocular pressure.
